News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,786 Results
Type
Article (14203)
Company Profile (282)
Press Release (252301)
Section
Business (79516)
Career Advice (153)
Deals (13227)
Drug Delivery (35)
Drug Development (50445)
Employer Resources (31)
FDA (5718)
Job Trends (5129)
News (144405)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21646)
ALS (61)
Alzheimer's disease (835)
Antibody-drug conjugate (ADC) (88)
Approvals (5735)
Artificial intelligence (112)
Autoimmune disease (13)
Automation (5)
Bankruptcy (104)
Best Places to Work (4562)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (45)
Brain cancer (20)
Breast cancer (142)
Cancer (1317)
Cardiovascular disease (112)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (308)
Cervical cancer (8)
Clinical research (40910)
Collaboration (499)
Compensation (226)
Complete response letters (13)
COVID-19 (1034)
CRISPR (37)
C-suite (146)
Cystic fibrosis (76)
Data (1379)
Denatured (11)
Depression (29)
Diabetes (126)
Diagnostics (1294)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (79)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (83)
Earnings (29688)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48181)
Executive appointments (409)
FDA (6346)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (467)
Gene editing (89)
Generative AI (9)
Gene therapy (234)
GLP-1 (358)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6590)
Huntington's disease (21)
IgA nephropathy (21)
Immunology and inflammation (80)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (58)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (203)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (187)
Lymphoma (84)
Machine learning (1)
Management (7)
Manufacturing (116)
MASH (49)
Medical device (2591)
Medtech (2592)
Mergers & acquisitions (6259)
Metabolic disorders (366)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (61)
Neuropsychiatric disorders (23)
Neuroscience (1211)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1563)
Now hiring (21)
Obesity (186)
Opinion (100)
Ovarian cancer (60)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (109)
Partnered (8)
Patents (112)
Patient recruitment (67)
Peanut (35)
People (25522)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14445)
Phase II (19034)
Phase III (12035)
Pipeline (741)
Podcasts (47)
Policy (38)
Postmarket research (852)
Preclinical (6067)
Press Release (30)
Prostate cancer (55)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (277)
Real estate (1415)
Recruiting (12)
Regulatory (8572)
Reports (15)
Research institute (937)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (56)
Series A (91)
Series B (60)
Service/supplier (1)
Sickle cell disease (39)
Southern California (1390)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1972)
State (1)
Stomach cancer (4)
Supply chain (18)
Tariffs (3)
The Weekly (35)
United States (12243)
Vaccines (205)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (51)
Last 7 days (434)
Last 30 days (1625)
Last 365 days (19980)
2025 (4908)
2024 (20552)
2023 (22421)
2022 (26822)
2021 (27809)
2020 (23362)
2019 (16232)
2018 (11741)
2017 (13749)
2016 (11842)
2015 (14353)
2014 (10394)
2013 (7488)
2012 (7535)
2011 (7616)
2010 (7431)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17229)
Australia (2921)
California (3553)
Canada (1058)
China (325)
Colorado (138)
Connecticut (143)
Delaware (88)
Europe (37065)
Florida (421)
Georgia (109)
Idaho (16)
Illinois (214)
India (9)
Indiana (86)
Iowa (1)
Japan (71)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (446)
Massachusetts (2813)
Michigan (69)
Minnesota (137)
Mississippi (1)
Missouri (23)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (891)
New Mexico (12)
New York (967)
North Carolina (525)
North Dakota (4)
Northern California (1563)
Ohio (108)
Oklahoma (9)
Oregon (21)
Pennsylvania (680)
Puerto Rico (3)
Rhode Island (15)
South America (209)
South Carolina (4)
Southern California (1390)
Tennessee (25)
Texas (412)
Utah (48)
Virginia (70)
Washington D.C. (28)
Washington State (322)
Wisconsin (13)
266,786 Results for "dragonfly therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announced that it has entered into a clinical collaboration with Merck, to evaluate DF9001, Dragonfly’s EGFR immune engager, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with advanced solid tumors expressing EGFR.
May 21, 2024
·
3 min read
Genetown
Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly’s DF1001 HER-2 TriNKET® with Gilead’s Trodelvy® in two Cancer Indications
Dragonfly Therapeutics, Inc. announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly’s TriNKET technology platform and Dragonfly’s lead clinical asset, with Trodelvy, Gilead’s Trop-2-directed antibody drug conjugate, in metastatic breast cancer and non-small cell lung cancer.
February 15, 2024
·
3 min read
Press Releases
Dragonfly Therapeutics Appoints Dr. Susan Altschuller as Chief Financial Officer
August 5, 2024
·
2 min read
Drug Development
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
Dragonfly Therapeutics, Inc. announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie to evaluate ABBV-303, a solid tumor targeting TriNKET®.
March 5, 2024
·
2 min read
Drug Development
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
Dragonfly Therapeutics, Inc. today announced it recently dosed its first patient in a Phase 1/1b study of the Company’s proprietary IL-2 investigational immunotherapy, DF6215, developed for patients with advanced solid tumors.
December 5, 2023
·
3 min read
Press Releases
Dragonfly Therapeutics to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at the Society for Immunotherapy of Cancer (SITC) Annual Conference
November 7, 2024
·
5 min read
Business
Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
Dragonfly Therapeutics, Inc. today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly’s novel IL12 cytokine DF6002/BMS-986415.
January 6, 2023
·
2 min read
Genetown
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago.
June 5, 2023
·
5 min read
Drug Development
Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy Dose Escalation Results at ASCO 2023 Annual Meeting
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced an oral presentation of Phase 1 DF1001 Monotherapy Dose Escalation Results scheduled on Sunday June 4, from 11:45 - 11:57 a.m.
June 2, 2023
·
3 min read
Drug Development
Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced it now owns all rights to develop DF6002, its novel interleukin-12 (IL-12) cytokine investigational immunotherapy program, which is in Phase 1 clinical development, with dose escalation progressing successfully in monotherapy and in combination with nivolumab, in the U.S. and in Europe.
February 6, 2023
·
3 min read
1 of 26,679
Next